ANBENITAMAB REPODATECAN
UNII 3U4SXA9ADW
Substance Identification & Data
This profile provides standardized clinical and technical data for Anbenitamab Repodatecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 3U4SXA9ADW.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2923420-38-4 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
3U4SXA9ADW
2923420-38-4
N/A
Detailed Substance Profile
Preferred Name
ANBENITAMAB REPODATECAN
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
INN ID
13457
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Anbenitamab Repodatecan
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Anbenitamab Repodatecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Anbenitamab Repodatecan
Common Names & Synonyms
Immunoglobulin G1 [369-serine,371-alanine,408-lysine,410-valine], anti-(human epidermal growth factor receptor HER2 domain IV) (human-Mus musculus monoclonal rhuMab 4D5 γ1-chain), disulfide with human-Mus musculus monoclonal rhuMab 4D5 κ-chain, (229→228′),(232→231′)-bis(disulfide) with immunoglobulin G1 [368-tryptophan,411-alanine] anti-(human epidermal growth factor receptor HER2 domain II) (human-Mus musculus monoclonal rhuMab 2C4 γ1-chain) disulfide with human-Mus musculus monoclonal rhuMab 4D5 κ-chain, 300,299′-bis[N-[O-2-[(2-azidoacetyl)amino]-2-deoxy-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→3)-O-[O-2-[(2-azidoacetyl)amino]-2-deoxy-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl-(1→6)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-O-[6-deoxy-α-L-galactopyranosyl-(1→6)]-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-L-asparagine], click reaction product with N-[20-(11,12-didehydrodibenz[b,f]azocin-5(6H)-yl)-1,17,20-trioxo-4,7,10,13-tetraoxa-16-azaeicos-1-yl]glycylglycyl-L-phenylalanyl-N-[[2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-2-oxoethoxy]methyl]glycinamide (1:4)
anbenitamab repodatecan [INN]
immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (epidermal growth factor receptor 2, receptor tyrosine protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody, bispecific biparatopic, tetravalent, conjugated at O-4 of the four terminal GlcNAc groups of the two branched glycans to a repodatecan group, consisting of a cleavable linker and a camptothecin derivative; H-gamma1 heavy chain anti-ERBB2 domain II humanized (1-449) [VH (Homo sapiens IGHV3-66*01 (78.8%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.12] (26-33.51-58.97-108)) (1-119) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, 14-G1v32 CH3 W22 (knob), 18-G1v82-4 CH3 A88(CH1 K120 (216) (120-217), hinge 1-15 (218-232), CH2 (233-342), CH3 D12 (358), L14 (360), T22>W (368), K88>A (411) (343-447), CHS (448-449)) (120-449)], (222-214')-disulfide with L-kappa light chain anti-ERBB2 humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01 (86.3%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') - Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; H-gamma1 heavy chain anti-ERBB2 domain IV humanized (1''-450'') [VH (Homo sapiens IGHV3-66*01 (81.6%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.13] (26''-33''.51''-58''.97''-109'')) (1''-120'') -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, 14-G1v33 CH3 S22, A24, V86(hole), 18-G1v82-3 CH3 K85.1 (CH1 K120 (217'') (121''-218''), hinge 1-15 (219''-233''), CH2 (234''-343''), CH3 D12 (359), L14 (361) T22>S (369''), L24>A (371''), F85.1>K (408''), Y86>V (410'') (344''-448''), CHS (449''-450'')) (121''-450'')], (223''-214''')-disulfide with L-kappa light chain anti-ERBB2 humanized (1'''-214''') [V-KAPPA (Homo sapiens IGKV1-39*01 (86.3%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27'''-32'''.50'''-52'''.89'''-97''')) (1'''-107''') - Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'''), V101 (191''')) (108'''-214''')]; dimer (228-229'':231-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa, substituted at O-4 of the four distal 2-acetamido-2-deoxy-β-D-glucopyranosyl groups of the two glycans at N-4 of the asparaginyl residues 299 and 300'' with 2-(2-{8-[(10S)-10-benzyl-1-{[(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]amino}-1,6,9,12,15,18,34-heptaoxo-3,21,24,27,30-pentaoxa-5,8,11,14,17,33-hexaazaheptatriacontan-37-oyl]-8,9-dihydro-1(or 3)H-dibenzo[b,f][1,2,3]triazolo[4,5-d]azocin-1(or 3)-yl}acetamido)-2-deoxy-β-D-galactopyranosyl (repodatecan) groups (introduced by enzymatic glycosylation with 2-(2-azidoacetamido)-2-deoxy-Dgalactopyranose and subsequent reaction of the azido groups with the specific click reagent), resulting in a drug/antibody ratio of ~3.8 on average
